Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29016496 | 0.87 | LPL (0.51) | LPLLIPGEGFRROCK1CA1 | |
| SCHEMBL239104 | 0.85 | LPL (0.56) | LPLLIPGEGFRROCK1CA1 | |
| SCHEMBL14616470 | 0.81 | LPL (0.53) | LPLLIPGEGFRROCK1CA1 | |
| SCHEMBL20648243 | 0.81 | LPL (0.53) | LPLLIPGEGFRROCK1CA1 | |
| SCHEMBL31550445 | 0.81 | LPL (0.53) | LPLLIPGEGFRROCK1CA1 | |
| SCHEMBL32663644 | 0.81 | LPL (0.46) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL14956320 | 0.81 | LPL (0.47) | LPLLIPGEGFRROCK1CA1 | |
| Ammonia Solution, Strong SCHEMBL18497260 | 0.80 | LPL (0.51) | LPLLIPGEGFRROCK1CA1 | |
| SCHEMBL1437613 | 0.80 | EGFR (0.55) | LPLLIPGEGFRROCK1CA1 | |
| SCHEMBL12496719 | 0.80 | LPL (0.51) | LPLLIPGEGFRROCK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154979-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | PFIZER LTD (GB) | 2018-03-07 | — | — | EP | disclosed |
| US-9802945-B2 | Imidazopyridazine derivatives as modulators of the GABAA receptor activity | PFIZER LIMITED (GB) | 2017-10-31 | — | — | US | disclosed |
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | PFIZER LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3154979-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | Pfizer Limited (GB) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189744-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY. | PFIZER LIMITED (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197965-A1 | Imidazopyridazine Derivatives As Modulators of the GABAA Receptor Activity | GABRA5, GABRA3, GABRA2 | LPL 4447/4885LIPG 4862/4885EGFR 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.